Abstract
One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5´- monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.
Keywords: Boron neutron capture therapy, carboranes, nucleosides, thymidine kinase, 3-carboranyl thymidine analogues, 3CTAs, N5-2OH
Anti-Cancer Agents in Medicinal Chemistry
Title: 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy
Volume: 6 Issue: 2
Author(s): Youngjoo Byun, Sureshbabu Narayanasamy, Jayaseharan Johnsamuel, Achintya K. Bandyopadhyaya, Rohit Tiwari, Ashraf S. Al-Madhoun, Rolf F. Barth, Staffan Eriksson and Werner Tjarks
Affiliation:
Keywords: Boron neutron capture therapy, carboranes, nucleosides, thymidine kinase, 3-carboranyl thymidine analogues, 3CTAs, N5-2OH
Abstract: One category of boron neutron capture therapy (BNCT) agents that has received extensive attention during recent years is 3-carboranyl thymidine analogues (3CTAs). These molecules are phosphorylated to the corresponding 5´- monophosphates by human thymidine kinase 1 (TK1), an enzyme that is up-regulated in dividing malignant cells. Thus, these phosphorylated molecules are selectively entrapped in tumor cells due to the acquired negative charge. This review will analyze design strategies applied for the synthesis of boron-containing nucleosides in general and in particular reference to 3CTAs. Results of biological studies with these molecules will be discussed.
Export Options
About this article
Cite this article as:
Byun Youngjoo, Narayanasamy Sureshbabu, Johnsamuel Jayaseharan, Bandyopadhyaya K. Achintya, Tiwari Rohit, Al-Madhoun S. Ashraf, Barth F. Rolf, Eriksson Staffan and Tjarks Werner, 3-Carboranyl Thymidine Analogues (3CTAs) and Other Boronated Nucleosides for Boron Neutron Capture Therapy, Anti-Cancer Agents in Medicinal Chemistry 2006; 6 (2) . https://dx.doi.org/10.2174/187152006776119171
DOI https://dx.doi.org/10.2174/187152006776119171 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Relationship with Programmed Cell Death Ligand 1 (PD-L1) and DTI Features in Brain Metastases of Non-small Cell Lung Cancer: A Preliminary Study
Current Medical Imaging PET Tracers for Mapping Adenosine Receptors as Probes for Diagnosis of CNS Disorders
Central Nervous System Agents in Medicinal Chemistry Cancer Neovascularization and Proinflammatory Microenvironments
Current Cancer Drug Targets 2´,3´-Dialdehyde of ATP, ADP, and Adenosine Inhibit HIV-1 Reverse Transcriptase and HIV-1 Replication
Current HIV Research Heterocyclic Curcumin Derivatives of Pharmacological Interest: Recent Progress
Current Topics in Medicinal Chemistry Radioprotective Gene Therapy
Current Gene Therapy Exosomal miR-214-5p Released from Glioblastoma Cells Modulates Inflammatory Response of Microglia after Lipopolysaccharide Stimulation through Targeting CXCR5
CNS & Neurological Disorders - Drug Targets Development of Novel Therapeutic Strategies for Lung Cancer: Targeting the Cholinergic System
Current Medicinal Chemistry Death Receptor Signaling in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Role of ABC Transporters in the Chemoresistance of Human Gliomas
Current Cancer Drug Targets Efficacy and Safety of Bevacizumab in Glioblastomas
Current Medicinal Chemistry Recent Advances in Metal-Organic Frameworks as Anticancer Drug Delivery Systems: A Review
Anti-Cancer Agents in Medicinal Chemistry Interlinking of Hypoxia and Estrogen in Thyroid Cancer Progression
Current Medicinal Chemistry Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia
Recent Patents on Anti-Cancer Drug Discovery Recently Patented Applications of Homologous Cellular and Extracellular Agents as Therapeutics or Targets for the Prevention of Restenosis Post- Angioplasty
Recent Patents on Cardiovascular Drug Discovery CXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
Recent Patents on Anti-Cancer Drug Discovery <i>Uncaria tomentosa</i> (Willd. ex Schult.): Focus on Nutraceutical Aspects
Current Bioactive Compounds Transductional Targeting with Recombinant Adenovirus Vectors
Current Gene Therapy Techniques and Methods for In Vivo MRI Monitoring of Exogenous and Endogenous Neural Stem Cell-Mediated Brain Repair
Recent Patents on Regenerative Medicine The Role of DNA Methylation in the Pathogenesis and Treatment of Cancer
Current Clinical Pharmacology